Ambrogio C*, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA*. KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. Cell. 2018 Jan 4. *Co-corresponding author. PMID: 29336889.
This is the first paper demonstrating that WT KRAS hampers the activity of mutant KRAS by a dimerization-dependent mechanism.
Ambrogio C*, Gómez-López G, Falcone M, Villanueva A, Crosetto N, Blasco R, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Serrano M, Hidalgo M, Santamaría D*, Barbacid M*. Combined inhibition of Ddr1 and Notch signaling as an effective therapeutic strategy for K-Ras-driven/p53-null lung adenocarcinomas. Nat Med. 2016 Feb 8. *Co-corresponding author. PMID: 26855149.
We demonstrated here that a gene expression signature corresponding to malignant K-Ras-driven tumors is acquired much earlier than what is conventionally accepted, even at the stage of early lesions of few hundred cells.
Nieto P, Ambrogio C, de Esteban L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D. A B-Raf kinase inactive mutant induces lung adenocarcinoma. Nature. 2017 Aug 2. PMID: 28783725.
This paper describes the discovery of BRAF inactivating mutations as new driven oncogenes in lung adenocarcinoma.
Ambrogio C*, Barbacid M, Santamaría D*. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene. 2016 Oct 24. *Co-corresponding author. PMID: 27775074.
This study demonstrated that concomitant expression of both KRAS and EGFR oncogenes is detrimental for tumor progression resulting in oncogenic toxicity.
Choudhari R, Minero VG, Menotti M, Pulito R, Brakebusch C, Compagno M, Voena C, Ambrogio C*, Chiarle R*. Non redundant roles for Cdc42 and Rac1 in ALK-rearranged lymphoma. Blood. 2016 Jan 8. *Co-last author. PMID: 26747246.
This paper describes the role of the Rho family GTPases in the pathogenesis of anaplastic large cell lymphoma in vivo.
Mysore VP*, Zhou Z*, Ambrogio C*, Wang Q, Okoro J, Jänne PA, Westover KD, Shan Y, Shaw DE. Structural model of a Ras-Raf signalosome. *equally contributed. bioRxiv, 2020 July 15, doi: https://doi.org/10.1101/2020.07.15.165266
This is the first paper describing an atomistic structural model for KRAS signalosome assembly at the plasma membrane.
Wang H, Lv Q, Xu Y, Cai Z, Zheng J, Chen X, Dai Y, Jänne PA, Ambrogio C* and Köhler J*. An integrative pharmacogenomics analysis identifies CK2 alpha as a promising therapeutic target in KRAS(G12C) mutant lung cancer. EBioMedicine. 2019 Nov. *Co-last author. PMID: 31668570
Here we developed and validated an integrative pharmacogenomics analysis to identify potential drug targets to overcome inhibitor resistance in lung cancer cell lines with KRAS mutations.
Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D and Ambrogio C. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. JCI Insights. 2020 Aug 6.
In this study, we characterized the potential role of DDR1 as predictive and prognostic biomarker for chemotherapy response in LUAD patients.
